Sana Biotechnology, Inc. (SANA)
SANANASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$1.91
-0.1050 (-5.22%) today
Regular session, Nov 13, 1:00 PM ET
- Market cap
- $570.80m
- P/E
- –
- EPS, last 4 quarters
- $-0.5700
- Dividend yield
- –
- Day range
- $1.86 to $2.05
- 52-week range
- $2.00 to $5.49
- Average volume
- –
- Previous close
- $2.01
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $8.00, +319.9% from here
Earnings
next estimate $-0.1200Next report
Dec 2025
-23.1%
Mar 2026
+6.7%
Jun 2026
+13.3%
Sep 2026
+22.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$61.20m | -$48.61m | -$65.42m | $18.51m |
| Net income | -$58.83m | -$47.21m | -$63.63m | $20.40m |
News
8 latest- Sana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical Trials RTTNews · Nov 6, 2026
- 3 Promising Genomics Stocks to Add to Your Portfolio in 2026Zacks · Jul 20, 2026
- Sana (SANA) Upgraded to Buy: Here's What You Should KnowZacks · Jul 15, 2026
- Weekly Buzz: FDA Okays TVTX, PHG; Rejects REPL; AIP Snaps Up AVNS; PDS, HOTH, SYRE, Paces Trials RTTNews · Apr 17, 2026
- Sana Announces Strategic Collaboration With Mayo Clinic For Developing Type-1 Diabetes Therapy SC451 RTTNews · Apr 14, 2026
- Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal RTTNews · Mar 20, 2026
- Sana Biotechnology Reports Continued Positive 14-Month Results In Type 1 Diabetes Cell-Therapy Study RTTNews · Mar 13, 2026
- Sana Biotech's Q4 Net Loss Expands; Plans To Submit IND For SC451 In 2026; Stock Down RTTNews · Mar 4, 2026
The company
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- sana.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.